Shares of NYSE:ISR opened at $0.27 on Wednesday. Isoray has a fifty-two week low of $0.25 and a fifty-two week high of $0.85. The stock has a 50-day simple moving average of $0.30. The stock has a market cap of $38.37 million, a price-to-earnings ratio of -5.40 and a beta of 1.03.
Isoray (NYSE:ISR – Get Rating) last issued its earnings results on Tuesday, May 10th. The company reported ($0.01) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.01). The business had revenue of $2.91 million during the quarter, compared to analyst estimates of $3.15 million. Isoray had a negative return on equity of 9.60% and a negative net margin of 56.86%. As a group, sell-side analysts anticipate that Isoray will post -0.05 EPS for the current fiscal year.
Isoray, Inc, through its subsidiary, IsoRay Medical, Inc, develops, manufactures, and sells isotope-based medical products and devices for the treatment of cancer and other malignant diseases in the United States and internationally. The company offers CS-1 Cesium-131 brachytherapy seeds for the treatment of prostate, brain, lung, head and neck, gynecological, pelvic/abdominal, and colorectal cancers.
- Get a free copy of the StockNews.com research report on Isoray (ISR)
- Zai Lab Stock Has Fallen to Value Levels
- Are These Cheap Copper Stocks Right For Your Portfolio?
- It’s A Comfortable Time To Buy Steelcase
- Worthington Posts Strong Results, But Earnings Fall On One-Off Adjustments
- A Tasty Entry Point Into Darden Restaurants International
Receive News & Ratings for Isoray Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Isoray and related companies with MarketBeat.com's FREE daily email newsletter.